<DOC>
	<DOC>NCT00945035</DOC>
	<brief_summary>This study will establish the bioequivalence of the 20%, milled, roller compaction final market image (FMI) etoricoxib tablets and 30% unmilled, roller compaction (UMC) etoricoxib tablets.</brief_summary>
	<brief_title>Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)</brief_title>
	<detailed_description />
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Subject is in good health Subject agrees to follow the study guidelines Subject is a smoker Subject has a history of adverse reactions caused by NSAIDs or allergies/intolerance to NSAIDs Subject is in a situation or has a condition/disease which may interfere with optimal participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>